Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.80 Consensus Target Price from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $22.80.

A number of analysts have issued reports on the company. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Tuesday, October 14th. Finally, JMP Securities dropped their target price on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 13th.

Insider Buying and Selling at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 19,500 shares of the company’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $10.82, for a total transaction of $210,990.00. Following the sale, the chief executive officer directly owned 222,016 shares of the company’s stock, valued at $2,402,213.12. This represents a 8.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors have recently modified their holdings of ZVRA. Woodline Partners LP raised its stake in shares of Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock valued at $34,571,000 after acquiring an additional 476,032 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Zevra Therapeutics by 15.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares during the period. Vanguard Group Inc. raised its position in Zevra Therapeutics by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock valued at $29,323,000 after purchasing an additional 130,676 shares in the last quarter. Nantahala Capital Management LLC raised its position in Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after purchasing an additional 500,000 shares in the last quarter. Finally, Rubric Capital Management LP boosted its stake in shares of Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after buying an additional 740,584 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Trading Down 5.0%

NASDAQ ZVRA opened at $8.60 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 7.81. The stock has a market capitalization of $484.16 million, a P/E ratio of -40.95 and a beta of 1.52. The firm’s 50-day moving average is $9.70 and its two-hundred day moving average is $9.70. Zevra Therapeutics has a 12 month low of $6.19 and a 12 month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $26.06 million during the quarter, compared to analysts’ expectations of $26.64 million. Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. On average, sell-side analysts anticipate that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.